Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 10

The DOI matches its Crossref record.

Rheostatic Regulation of the SERCA/Phospholamban Membrane Protein Complex Using Non-Coding RNA and Single-Stranded DNA oligonucleotides

Soller, Kailey J., Verardi, Raffaello, Jing, Meng, Abrol, Neha, Yang, Jing, Walsh, Naomi, Vostrikov, Vitaly V., Robia, Seth L., Bowser, Michael T., Veglia, Gianluigi · 2015 · Scientific Reports

Abstract

The membrane protein complex between sarco(endo)plasmic reticulum Ca 2+-ATPase (SERCA) and phospholamban (PLN) is a prime therapeutic target for reversing cardiac contractile dysfunctions caused by calcium mishandling. So far, however, efforts to develop drugs specific for this protein complex have failed. Here, we show that non-coding RNAs and single-stranded DNAs (ssDNAs) interact with and regulate the function of the SERCA/PLN complex in a tunable manner. Both in HEK cells expressing the SERCA/PLN complex, as well as in cardiac sarcoplasmic reticulum preparations, these short oligonucleotides bind and reverse PLN’s inhibitory effects on SERCA, increasing the ATPase’s apparent Ca 2+ affinity. Solid-state NMR experiments revealed that ssDNA interacts with PLN specifically, shifting the conformational equilibrium of the SERCA/PLN complex from an inhibitory to a non-inhibitory state. Importantly, we achieved rheostatic control of SERCA function by modulating the length of ssDNAs. Since restoration of Ca 2+ flux to physiological levels represents a viable therapeutic avenue for cardiomyopathies, our results suggest that oligonucleotide-based drugs could be used to fine-tune SERCA function to counterbalance the extent of the pathological insults.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep13000

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 52

  1. Go, A. S. et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129, e28–e292, 10.1161/01.cir.0000441139.02102.80 (2014). · DOI · Paper page
  2. Kho, C., Lee, A. & Hajjar, R. J. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. Nature reviews. Cardiology 9, 717–733, 10.1038/nrcardio.2012.145 (2012). · DOI · Paper page
  3. Davis, J. et al. Designing heart performance by gene transfer. Physiological reviews 88, 1567–1651, 10.1152/physrev.00039.2007 (2008). · DOI
  4. Gwathmey, J. K., Yerevanian, A. & Hajjar, R. J. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. Human gene therapy 24, 937–947, 10.1089/hum.2013.2512 (2013). · DOI
  5. Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198–205, 10.1038/415198a (2002). · DOI · Paper page
  6. MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nature reviews. Molecular cell biology 4, 566–577, 10.1038/nrm1151 (2003). · DOI · Paper page
  7. Haghighi, K., Gregory, K. N. & Kranias, E. G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochemical and biophysical research communications 322, 1214–1222, 10.1016/j.bbrc.2004.07.164 (2004). · DOI
  8. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (New York, N.Y.) 299, 1410–1413, 10.1126/science.1081578 (2003). · DOI · Paper page
  9. Greenberg, B. et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC. Heart failure 2, 84–92, 10.1016/j.jchf.2013.09.008 (2014). · DOI · Paper page
  10. Kairouz, V., Lipskaia, L., Hajjar, R. J. & Chemaly, E. R. Molecular targets in heart failure gene therapy: current controversies and translational perspectives. Annals of the New York Academy of Sciences 1254, 42–50, 10.1111/j.1749-6632.2012.06520.x (2012). · DOI
  11. Bish, L. T. et al. Cardiac Gene Transfer of Short Hairpin RNA Directed Against Phospholamban Effectively Knocks Down Gene Expression but Causes Cellular Toxicity in Canines. Human gene therapy 22, 969–977, 10.1089/hum.2011.035 (2011). · DOI
  12. Wahlquist, C. et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531–535, 10.1038/nature13073 (2014). · DOI · Paper page
  13. Tanaka, Y., Honda, T., Matsuura, K., Kimura, Y. & Inui, M. In vitro selection and characterization of DNA aptamers specific for phospholamban. The Journal of pharmacology and experimental therapeutics 329, 57–63, 10.1124/jpet.108.149526 (2009). · DOI
  14. Sakai, H. et al. A cell-penetrating phospholamban-specific RNA aptamer enhances Ca transients and contractile function in cardiomyocytes. Journal of molecular and cellular cardiology 76C, 177–185, 10.1016/j.yjmcc.2014.09.006 (2014). · DOI
  15. Kiriazis, H. et al. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovascular research 53, 372–381 (2002). · DOI
  16. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. The Journal of clinical investigation 111, 869–876, 10.1172/JCI17892 (2003). · DOI · Paper page
  17. Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nature medicine 8, 864–871, 10.1038/nm739 (2002). · DOI · Paper page
  18. Ha, K. N., Gustavsson, M. & Veglia, G. Tuning the structural coupling between the transmembrane and cytoplasmic domains of phospholamban to control sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) function. Journal of muscle research and cell motility 33, 485–492, 10.1007/s10974-012-9319-4 (2012). · DOI
  19. Ha, K. N. et al. Controlling the inhibition of the sarcoplasmic Ca2+-ATPase by tuning phospholamban structural dynamics. The Journal of biological chemistry 282, 37205–37214, 10.1074/jbc.M704056200 (2007). · DOI
  20. Simmerman, H. K., Collins, J. H., Theibert, J. L., Wegener, A. D. & Jones, L. R. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. The Journal of biological chemistry 261, 13333–13341 (1986). · doi:10.1016/s0021-9258(18)69309-3
  21. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nature reviews. Drug discovery 9, 537–550, 10.1038/nrd3141 (2010). · DOI · Paper page
  22. Simmerman, H. K. & Jones, L. R. Phospholamban: protein structure, mechanism of action and role in cardiac function. Physiological reviews 78, 921–947 (1998). · DOI · Paper page
  23. Kelly, E. M., Hou, Z., Bossuyt, J., Bers, D. M. & Robia, S. L. Phospholamban Oligomerization, Quaternary Structure and Sarco(endo)plasmic Reticulum Calcium ATPase Binding Measured by Fluorescence Resonance Energy Transfer in Living Cells. Journal of Biological Chemistry 283, 12202–12211, 10.1074/jbc.M707590200 (2008). · DOI
  24. Bidwell, P., Blackwell, D. J., Hou, Z., Zima, A. V. & Robia, S. L. Phospholamban Binds with Differential Affinity to Calcium Pump Conformers. Journal of Biological Chemistry 286, 35044–35050, 10.1074/jbc.M111.266759 (2011). · DOI · Paper page
  25. Ha, K. N. et al. Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America 108, 2735–2740, 10.1073/pnas.1013987108 (2011). · DOI
  26. Hou, Z., Kelly, E. M. & Robia, S. L. Phosphomimetic Mutations Increase Phospholamban Oligomerization and Alter the Structure of Its Regulatory Complex. Journal of Biological Chemistry 283, 28996–29003, 10.1074/jbc.M804782200 (2008). · doi:10.1074/jbc.m804782200
  27. Thomas, D. M., Bendall, M. R., Pegg, D. T., Doddrell, D. M. & Field, J. Two-dimensional 13C•1H polarization transfer J spectroscopy. Journal of Magnetic Resonance (1969) 42, 298–306, http://dx.doi.org/10.1016/0022-2364(81)90219-5 (1981). · doi:10.1016/0022-2364(81)90219-5
  28. Gustavsson, M. et al. Allosteric regulation of SERCA by phosphorylation-mediated conformational shift of phospholamban. Proceedings of the National Academy of Sciences of the United States of America, 10.1073/pnas.1303006110 (2013). · DOI · Paper page
  29. Son, W. S. et al. ‘q-Titration’ of long-chain and short-chain lipids differentiates between structured and mobile residues of membrane proteins studied in bicelles by solution NMR spectroscopy. Journal of Magnetic Resonance 214, 111–118, http://dx.doi.org/10.1016/j.jmr.2011.10.011 (2012). · doi:10.1016/j.jmr.2011.10.011
  30. Kranias, E. G. & Hajjar, R. J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circulation research 110, 1646–1660, 10.1161/CIRCRESAHA.111.259754 (2012). · DOI · Paper page
  31. Shamoo, Y., Friedman, A. M., Parsons, M. R., Konigsberg, W. H. & Steitz, T. A. Crystal structure of a replication fork single-stranded DNA binding protein (T4 gp32) complexed to DNA. Nature 376, 362–366 (1995). · DOI · Paper page
  32. Revzin, A. The Biology of Nonspecific DNA-Protein Interactions. (CRC Press, 1990).
  33. Dickey, T. H., Altschuler, S. E. & Wuttke, D. S. Single-Stranded DNA-Binding Proteins: Multiple Domains for Multiple Functions. Structure 21, 1074–1084, http://dx.doi.org/10.1016/j.str.2013.05.013 (2013). · DOI
  34. Kumarswamy, R. & Thum, T. Non-coding RNAs in cardiac remodeling and heart failure. Circulation research 113, 676–689, 10.1161/CIRCRESAHA.113.300226 (2013). · DOI · Paper page
  35. Bronze-da-Rocha, E. MicroRNAs Expression Profiles in Cardiovascular Diseases. BioMed Research International. 2014, 23, 10.1155/2014/985408 (2014). · DOI · Paper page
  36. Duan, L., Xiong, X., Liu, Y. & Wang, J. miRNA-1: functional roles and dysregulation in heart disease. Molecular BioSystems, 10.1039/C4MB00338A (2014). · DOI
  37. Winbanks, C. E., Ooi, J. Y. Y., Nguyen, S. S., McMullen, J. R. & Bernardo, B. C. MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets? Clinical and Experimental Pharmacology and Physiology, n/a-n/a, 10.1111/1440-1681.12281 (2014). · DOI
  38. van Rooij, E. & Olson, E. N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nature reviews. Drug discovery 11, 860–872, 10.1038/nrd3864 (2012). · DOI · Paper page
  39. Dangwal, S. & Thum, T. microRNA therapeutics in cardiovascular disease models. Annual review of pharmacology and toxicology 54, 185–203, 10.1146/annurev-pharmtox-011613-135957 (2014). · DOI
  40. Bao, M.-H. et al. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. International journal of molecular sciences 14, 23086–23102, 10.3390/ijms141123086 (2013). · DOI · Paper page
  41. Gröβl, T. et al. A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. PloS one 9, e92188, 10.1371/journal.pone.0092188 (2014). · DOI
  42. Buck, B. et al. Overexpression, purification and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. Protein expression and purification 30, 253–261 (2003). · DOI · Paper page
  43. Stokes, D. L. & Green, N. M. Three-dimensional crystals of CaATPase from sarcoplasmic reticulum. Symmetry and molecular packing. Biophysical Journal 57, 1–14 (1990). · DOI
  44. Ablorh, N.-A. et al. Accurate quantitation of phospholamban phosphorylation by immunoblot. Analytical Biochemistry 425, 68–75, http://dx.doi.org/10.1016/j.ab.2012.01.028 (2012). · DOI
  45. Madden, T. D., Chapman, D. & Quinn, P. J. Cholesterol modulates activity of calcium-dependant ATPase of the sarcoplasmic reticulum. Nature 279, 538–541 (1979). · DOI
  46. Takegoshi, K., Nakamura, S. & Terao, T. in Chemical Physics Letters Vol. 344 631–637 (2001). · DOI · Paper page
  47. Delaglio, F. et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. Journal of Biomolecular NMR 6, 277–293, 10.1007/BF00197809 (1995). · DOI · Paper page
  48. Bowser, M. T. & Chen, D. D. Y. Monte Carlo Simulation of Error Propagation in the Determination of Binding Constants from Rectangular Hyperbolae. 2. Effect of the Maximum-Response Range. The Journal of Physical Chemistry A 103, 197–202, 10.1021/jp982917e (1999). · DOI
  49. Wei, a. P. & Herron, J. N. Use of synthetic peptides as tracer antigens in fluorescence polarization immunoassays of high molecular weight analytes. Analytical chemistry 65, 3372–3377 (1993). · DOI
  50. Onizuka, T., Endo, S., Hirano, M., Kanai, S. & Akiyama, H. Design of a Fluorescent Electrophoretic Mobility Shift Assay Improved for the Quantitative and Multiple Analysis of Protein-DNA Complexes. Bioscience, Biotechnology and Biochemistry 66, 2732–2734, 10.1271/bbb.66.2732 (2002). · doi:10.1271/bbb.66.2732
  51. Jing, M. & Bowser, M. T. Isolation of DNA aptamers using micro free flow electrophoresis. Lab on a chip 11, 3703–3709, 10.1039/c1lc20461k (2011). · DOI
  52. Zal, T. & Gascoigne, N. R. J. Photobleaching-Corrected FRET Efficiency Imaging of Live Cells. Biophysical Journal 86, 3923–3939, http://dx.doi.org/10.1529/biophysj.103.022087 (2004). · DOI · Paper page

Cited by

Metadata

Authors
Soller, K. J., Verardi, R., Jing, M., Abrol, N., Yang, J., Walsh, N., Vostrikov, V. V., Robia, S. L., Bowser, M. T., & Veglia, G.
Venue
Scientific Reports
Published
2015-08-21
Volume
5
Issue
1
ISSN
2045-2322
Cited by
10
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.